Medison, the creator of a unified global commercialization platform for breakthrough therapies, appointed Francis Wan as VP, GM Asia Pacific (APAC) and member of the company’s Global Leadership Team.

Francis will lead Medison’s strategy and operations across the APAC region, a critical growth area for the company’s platform. His expertise in rare diseases and oncology, together with his extensive experience in China’s healthcare landscape, adds a vital dimension to Medison’s strategy for the region.

With over 20 years of biopharmaceutical leadership experience, including serving as President Asia Pacific at Biogen and Managing Director of Commercial Operations at MSD China, he has successfully scaled organizations, advanced innovative therapies, and built sustainable access models across diverse APAC markets. 

Gil Gurfinkel, CEO of Medison, said, “With his appointment, we continue to advance toward completing our expansion roadmap and building a world leader and the best commercialization company for international markets. Francis’s extensive experience with healthcare systems and his proven record of creating access and commercial success in China and across APAC will strengthen our ability to accelerate access to life-changing therapies and deepen our partnerships in the region and on a global scale.”

“Across APAC, breakthrough therapies are still out of reach for many patients, leaving a vast and diverse population with significant unmet needs,” said Francis Wan. “Through Medison’s global commercialization platform, we have a unique opportunity to change this reality and expand access to breakthrough therapies. Having spent much of my career in China and across APAC, I understand firsthand how essential it is to deliver sustainable solutions and enable faster access for patients with rare and severe diseases.”